LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Holmes, M.V.; Simon, T.; Exeter, H.J.; Folkersen, L.; Asselbergs, F.W.; Guardiola, M.; Cooper, J.A.; Palmen, J.; Hubacek, J.A.; Carruthers, K.F.; Horne, B.D.; Brunisholz, K.D.; Mega, J.L.; van Iperen, E.P.A.; Li, M.; Leusink, M.; Trompet, S.; Verschuren, J.J.W.; Hovingh, G.K.; Dehghan, A.; Nelson, C.P.; Kotti, S.; Danchin, N.; Scholz, M.; Haase, C.L.; Rothenbacher, D.; Swerdlow, D.I.; Kuchenbaecker, K.B.; Staines-Urias, E.; Goel, A. ... view all 113 authors View less authors (2013)
Publisher: Elsevier Inc.
Languages: English
Types: Article
Subjects: MI, myocardial infarction, OR, odds ratio, LDL-C, low-density lipoprotein cholesterol, ARTERY-DISEASE, RCT, randomized clinical trial, Cardiology and Cardiovascular Medicine, SERUM-LEVELS, EPIC-NORFOLK, ACUTE CORONARY SYNDROMES, TRIAL, epidemiology, genetics, INHIBITOR, MVE, major vascular events, EVENTS, Cardiometabolic Risk, SNP, single-nucleotide polymorphism, drug development, sPLA2, secretory phospholipase A2, cardiovascular diseases, CI, confidence interval, ACS, acute coronary syndrome(s), Clinical Research, RISK, MENDELIAN RANDOMIZATION, HEALTHY-MEN
Objectives:\ud This study sought to investigate the role of secretory phospholipase A2 (sPLA2)-IIA in cardiovascular disease.

\ud \ud Background:\ud Higher circulating levels of sPLA2-IIA mass or sPLA2 enzyme activity have been associated with increased risk of cardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2 inhibitor (varespladib) was stopped prematurely for lack of efficacy.

\ud \ud Methods:\ud We conducted a Mendelian randomization meta-analysis of 19 general population studies (8,021 incident, 7,513 prevalent major vascular events [MVE] in 74,683 individuals) and 10 acute coronary syndrome (ACS) cohorts (2,520 recurrent MVE in 18,355 individuals) using rs11573156, a variant in PLA2G2A encoding the sPLA2-IIA isoenzyme, as an instrumental variable.

\ud \ud Results:\ud PLA2G2A rs11573156 C allele associated with lower circulating sPLA2-IIA mass (38% to 44%) and sPLA2 enzyme activity (3% to 23%) per C allele. The odds ratio (OR) for MVE per rs11573156 C allele was 1.02 (95% confidence interval [CI]: 0.98 to 1.06) in general populations and 0.96 (95% CI: 0.90 to 1.03) in ACS cohorts. In the general population studies, the OR derived from the genetic instrumental variable analysis for MVE for a 1-log unit lower sPLA2-IIA mass was 1.04 (95% CI: 0.96 to 1.13), and differed from the non-genetic observational estimate (OR: 0.69; 95% CI: 0.61 to 0.79). In the ACS cohorts, both the genetic instrumental variable and observational ORs showed a null association with MVE. Instrumental variable analysis failed to show associations between sPLA2 enzyme activity and MVE.

\ud \ud Conclusions:\ud Reducing sPLA2-IIA mass is unlikely to be a useful therapeutic goal for preventing cardiovascular events.

Share - Bookmark

Funded by projects

  • NIH | SOCIAL AND OCCUPATIONAL INF...
  • NIH | CHANGES IN HEALTH: SOCIO-EC...
  • NIH | Health behaviors over the a...
  • EC | PHASE
  • EC | FAD
  • RCUK | Centre for molecular-based...
  • NWO | NCHA Subsidiebesluit 2008-2012
  • WT | Understanding the genetic ba...

Cite this article